Versant Capital Management Inc Has $98,000 Stock Position in Humana Inc. (NYSE:HUM)

Versant Capital Management Inc lifted its position in Humana Inc. (NYSE:HUM) by 15.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 387 shares of the insurance provider’s stock after buying an additional 52 shares during the quarter. Versant Capital Management Inc’s holdings in Humana were worth $98,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in HUM. Commonwealth Equity Services LLC lifted its holdings in shares of Humana by 3.8% in the second quarter. Commonwealth Equity Services LLC now owns 20,896 shares of the insurance provider’s stock valued at $7,808,000 after purchasing an additional 763 shares in the last quarter. National Bank of Canada FI raised its position in Humana by 9.8% during the second quarter. National Bank of Canada FI now owns 54,394 shares of the insurance provider’s stock valued at $20,313,000 after buying an additional 4,854 shares during the period. Parkside Financial Bank & Trust lifted its stake in Humana by 51.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 419 shares of the insurance provider’s stock worth $157,000 after acquiring an additional 142 shares in the last quarter. Private Advisor Group LLC boosted its position in Humana by 45.3% during the 2nd quarter. Private Advisor Group LLC now owns 2,966 shares of the insurance provider’s stock worth $1,108,000 after acquiring an additional 925 shares during the period. Finally, Candriam S.C.A. grew its stake in Humana by 4.3% during the 2nd quarter. Candriam S.C.A. now owns 8,739 shares of the insurance provider’s stock valued at $3,265,000 after acquiring an additional 359 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 3.9 %

Humana stock opened at $262.47 on Friday. The business’s 50-day simple moving average is $272.60 and its 200-day simple moving average is $313.96. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $471.37. The firm has a market capitalization of $31.60 billion, a PE ratio of 23.25, a PEG ratio of 2.12 and a beta of 0.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities research analysts forecast that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.35%. Humana’s dividend payout ratio is 31.36%.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on HUM shares. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Leerink Partnrs downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and cut their price objective for the stock from $519.00 to $253.00 in a report on Monday, October 7th. Finally, Piper Sandler downgraded Humana from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Twenty equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $300.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.